Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (vol 378, pg 1931, 2011)

被引：0
|
作者：
Rini, B., I
Escudier, B.
Tomczak, P.
机构：
来源：
LANCET | 2012年 / 380卷 / 9856期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1818 / 1818
页数：1
相关论文
共 50 条
  • [31] TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
    Choueiri, T.
    Agarwal, N.
    Ho, T.
    Pal, S. K.
    Seon, B.
    Jivani, M.
    Adams, B.
    Shazer, R.
    Theuer, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus AXitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
    Choueiri, Toni K.
    Agarwal, Neeraj
    Ho, Thai H.
    Pachynski, Russell
    Pal, Sumanta
    Ryan, Christopher W.
    Vaena, Daniel
    Lara, Primo
    Lawler, William
    Posadas, Edwin
    Sonpavde, Guru P.
    Wang, Peng
    Gabrail, Nashat
    Hammers, Hans-Joerg
    Merchan, Jaime
    Olencki, Thomas
    Redman, Bruce
    Sean, Ben K.
    Adams, Bonne J.
    Theuer, Charles P.
    BJU INTERNATIONAL, 2015, 116 : 5 - 6
  • [33] AXITINIB VS SORAFENIB FOR ADVANCED RENAL CELL CARCINOMA: PHASE III OVERALL SURVIVAL RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS
    Motzer, R. J.
    Escudier, B.
    Tomczak, P.
    Negrier, S.
    Gore, M. E.
    Tarazi, J.
    Hariharan, S.
    Rosbrook, B.
    Kim, S.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2012, 23 : 262 - 262
  • [34] Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
    Rini, Brian I.
    Pal, Sumanta K.
    Escudier, Bernard J.
    Atkins, Michael B.
    Hutson, Thomas E.
    Porta, Camillo
    Verzoni, Elena
    Needle, Michael N.
    McDermott, David F.
    LANCET ONCOLOGY, 2020, 21 (01): : 95 - 104
  • [35] Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
    Karam, Jose A.
    Devine, Catherine E.
    Urbauer, Diana L.
    Lozano, Marisa
    Maity, Tapati
    Ahrar, Kamran
    Tamboli, Pheroze
    Tannir, Nizar M.
    Wood, Christopher G.
    EUROPEAN UROLOGY, 2014, 66 (05) : 874 - 880
  • [36] Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
    Yau, Thomas
    Park, Joong-Won
    Finn, Richard S.
    Cheng, Ann-Lii
    Mathurin, Philippe
    Edeline, Julien
    Kudo, Masatoshi
    Harding, James J.
    Merle, Philippe
    Rosmorduc, Olivier
    Wyrwicz, Lucjan
    Schott, Eckart
    Choo, Su Pin
    Kelley, Robin Kate
    Sieghart, Wolfgang
    Assenat, Eric
    Zaucha, Renata
    Furuse, Junji
    Abou-Alfa, Ghassan K.
    El-Khoueiry, Anthony B.
    Melero, Ignacio
    Begic, Damir
    Chen, Gong
    Neely, Jaclyn
    Wisniewski, Tami
    Tschaika, Marina
    Sangro, Bruno
    LANCET ONCOLOGY, 2022, 23 (01): : 77 - 90
  • [37] Phase II trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma
    Karam, Jose A.
    Devine, Catherine E.
    Urbauer, Diana L.
    Lozano, Marisa
    Ahrar, Kamran
    Tamboli, Pheroze
    Tannir, Nizar M.
    Wood, Christopher G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [38] Overall survival analysis from a randomised phase III trial of axitinib vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma
    Hutson, T. E.
    Al-Shukri, S.
    Stus, V. P.
    Lipatov, O. N.
    Shparyk, Y.
    Bair, A. H.
    Rosbrook, B.
    Andrews, G. I.
    Vogelzang, N. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S476 - S477
  • [39] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Spain
    Maroto, P.
    Villavicencio, H.
    Pinol, C.
    Urruticoechea, L.
    VALUE IN HEALTH, 2006, 9 (06) : A280 - A280
  • [40] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma.
    Gao, X.
    Reddy, P.
    Dhanda, R.
    Gondek, K.
    Yeh, Y. C.
    Stadler, W. M.
    Jonasch, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 242S - 242S
12345